In yesterday’s Q3 release, the drug development company focused on rare diseases revealed that approximately 95% of the required events have occurred in the Phase III Confirmatory Study for KIACTATM. This was 85% in August 2015. Being a double blind placebo controlled trial, to which the company does not have access to the data until completion of the study, no conclusion can be made over efficacy from this statistic. However it does suggest that the study is well on track to complete i
16 Nov 2015
Q3 update: Cash balance strong; key data on KIACTATM fast approaching.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 update: Cash balance strong; key data on KIACTATM fast approaching.
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
16 Nov 2015 -
Author:
Derren Nathan - Pages:
In yesterday’s Q3 release, the drug development company focused on rare diseases revealed that approximately 95% of the required events have occurred in the Phase III Confirmatory Study for KIACTATM. This was 85% in August 2015. Being a double blind placebo controlled trial, to which the company does not have access to the data until completion of the study, no conclusion can be made over efficacy from this statistic. However it does suggest that the study is well on track to complete i